Literature DB >> 1845972

Regulation of prostaglandin synthesis by thyrotropin, insulin or insulin-like growth factor-I, and serum in FRTL-5 rat thyroid cells.

K Tahara1, E F Grollman, M Saji, L D Kohn.   

Abstract

The present report shows that thyrotropin (TSH) regulates all three steps involved in prostaglandin synthesis in FRTL-5 rat thyroid cells, i.e. arachidonic acid release from membrane phospholipids, cyclooxygenase (prostaglandin H synthase) action, and individual prostaglandin formation; however, its action at specific steps may require the presence of, or can be duplicated by, insulin, insulin-like growth factor-I (IGF-I), and/or a serum factor. Thus, TSH releases free arachidonic acid from rat FRTL-5 thyroid cells whose phospholipid fraction is radiolabeled with [3H]arachidonic acid; this action involves a pertussis toxin-sensitive G protein, is not cAMP mediated, and does not require insulin or 5% serum. To quantitate TSH effects on cyclooxygenase activity and on individual prostaglandin formation, a homogenate system and a rapid reversed-phase high pressure liquid chromatography procedure have been developed to measure cyclooxygenase metabolites. TSH increased cyclooxygenase activity in homogenates only if the cells were also exposed to insulin, IGF-I, and/or 5% calf serum; TSH alone had no apparent effect on the activity. Maximal activation, 4-fold over basal/micrograms of DNA, took 36 h to achieve and reflected, at least in part, an increase in cyclooxygenase gene expression. Like cyclooxygenase activity, induction of prostaglandin E2 production required 2 or more factors, i.e. TSH plus insulin/IGF-I or TSH plus insulin/IGF-I plus serum. Increased production of prostaglandin D2, could, however, be detected if cells were treated with TSH alone and the TSH activity could be duplicated by insulin, IGF-I, or calf serum alone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845972

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Severe hyperprostaglandin E syndrome with hyperthyroidism--studies of pathogenetic mechanisms.

Authors:  V Fellman; H Pihko; A Majander; H W Seyberth
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

2.  Effect of sphingosine derivatives on calcium fluxes in thyroid FRTL-5 cells.

Authors:  K Törnquist; E Ekokoski
Journal:  Biochem J       Date:  1994-04-01       Impact factor: 3.857

3.  Regulation of myo-inositol transport during the growth and differentiation of thyrocytes: a link with thyroid-stimulating hormone-induced phospholipase A2 activity.

Authors:  G Grafton; M A Baxter; M C Sheppard; M C Eggo
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

4.  IGF-1 deficiency impairs neurovascular coupling in mice: implications for cerebromicrovascular aging.

Authors:  Peter Toth; Stefano Tarantini; Nicole M Ashpole; Zsuzsanna Tucsek; Ginger L Milne; Noa M Valcarcel-Ares; Akos Menyhart; Eszter Farkas; William E Sonntag; Anna Csiszar; Zoltan Ungvari
Journal:  Aging Cell       Date:  2015-07-14       Impact factor: 9.304

5.  CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.

Authors:  Chien-Chih Ke; Ren-Shyan Liu; An-Hang Yang; Ching-Sheng Liu; Chin-Wen Chi; Ling-Ming Tseng; Yi-Fan Tsai; Jennifer H Ho; Chen-Hsen Lee; Oscar K Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-19       Impact factor: 9.236

Review 6.  Bioassays for TSH Receptor Autoantibodies, from FRTL-5 Cells to TSH Receptor-LH/CG Receptor Chimeras: The Contribution of Leonard D. Kohn.

Authors:  Cesidio Giuliani; Motoyasu Saji; Ines Bucci; Giorgio Napolitano
Journal:  Front Endocrinol (Lausanne)       Date:  2016-07-25       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.